Exploring the Limits: The Challenge of Finding the Right Dose for Anti-Vascular Endothelial Growth Factor Treatment in Retinopathy of Prematurity

Ophthalmology. 2018 Dec;125(12):1967-1968. doi: 10.1016/j.ophtha.2018.08.018.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Bevacizumab
  • Humans
  • Infant, Newborn
  • Recurrence
  • Retinopathy of Prematurity*
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Bevacizumab